|Bid||54.02 x 2200|
|Ask||68.50 x 1800|
|Day's Range||53.85 - 55.14|
|52 Week Range||33.93 - 55.88|
|Beta (3Y Monthly)||0.90|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.35 (0.68%)|
|1y Target Est||N/A|
Benefiting from new products and an improved sales force performance, Integra LifeSciences (IART) projects speedy organic growth in the second half of 2019.
According to Medtronic (MDT), interbody implants material and shape play a vital role in the bone growth process during fusions and presently, titanium interbody devices are rapidly becoming popular.
Abbott (ABT) is attracting constant attention with developments in its flagship, sensor-based continuous glucose monitoring (CGM) system called FreeStyle Libre System.
National Vision's (EYE) consistent strength in comps is owing to higher customer transaction for the past 69 straight quarters.
Syneos Health (SYNH) sees strong year-over-year revenue growth across both operating segments ??? Clinical Solutions and Commercial Solutions.
Cardinal Health (CAH) Q3 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, sluggishness in the Medical segment remains a concern.
Bio-Rad (BIO) witnesses revenue growth at the Life Sciences segment in Q1 on strength in cell biology, droplet Digital PCR and other product lines.
Wright Medical (WMGI) Q1 results benefit from higher revenues, solid show by Lower as well as Upper Extremities segments and gross margin expansion. However, rising costs remain a woe.
Lower revenues, weak performing product segment and contraction in gross margin impact OPKO Health's (OPK) Q1 results.
Phibro Animal Health (PAHC) sees year-over-year revenue decline in two core segments ??? Animal Health and Mineral Nutrition.
McKesson's (MCK) Q4 results benefit from higher revenues, gross margin expansion and solid show by U.S. Pharmaceutical and Specialty Solutions.
Allscripts (MDRX) Q1 results gain from growth in bookings and solid show by client services segment. Contraction in margins remains a woe.